Noxopharm CEO Dr Gisela Mautner said, “We are very grateful to the Tour de Cure team for funding this promising research. With this grant, our preclinical drug candidate is recognised as having potential that warrants further investigation and development."
Sponsored
Latest Video
New Stories
-
Tour de Cure backs further development of Noxopharm's preclinical brain cancer candidate
April 24, 2024 - - Latest News -
Novartis nominates ex-BMS chief executive as its new chair
April 24, 2024 - - Latest News -
'The Pharmac system again, over about 33 years old, hasn’t really changed and evolved'
April 24, 2024 - - Latest News -
AusBiotech appoints experienced Sanofi leader as its new chief executive
April 23, 2024 - - Latest News -
Should principles such as 'equity' and 'opportunity cost' be applied consistently or not at all?
April 23, 2024 - - Latest News -
Rare Cancers Australia welcomes new appointments to its board of directors
April 23, 2024 - - Latest News -
BMS and Australian venture capital firm back immunotherapy company Pathios Therapeutics
April 23, 2024 - - Latest News